Coya Therapeutics, Inc. (COYA) Form 10-Q — May 12, 2026
Coya Therapeutics, Inc. reported a net loss of $7.2 million for the three months ended March 31, 2026, a slight improvement from the $7.3 million loss in the same period of 2025. The company's cash position as of March 31, 2026, was $50.7 million, up from $46.8 million at the end of 2025. This increase in cash is primarily due to a private placement of common stock in January 2026, which generated gross proceeds of approximately $11.1 million.
Key figures
- Revenue
- 251147
- Total Debt
- 4300739
- Cash Position
- 50724643
Price after filing
1 day: +5.8%7 days: +6.5%30 days: +2.8%
Close on the filing date to close N calendar days later (from $4.29). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.